Download MendeleySHP-1 agonist SC-43 limits methicillin-resistant Staphylococcus aureus infection through inhibition of heme biosynthesis.
Huang, Y., Ye, Y., Zhu, X., Liang, D., Cui, R., Yuan, X., Li, X., Zou, Q., Li, H., Huang, W.(2026) EMBO Mol Med 18: 1990-2005
- PubMed: 41963642 Search on PubMedSearch on PubMed Central
- DOI: https://doi.org/10.1038/s44321-026-00418-4
- Primary Citation Related Structures:
9VI5 - PubMed Abstract:
The limitations of existing drugs and the development of drug resistance make it urgent to develop new drugs against methicillin-resistant Staphylococcus aureus (MRSA). The re-development of the antibacterial activity of drugs that have already been proven safe for human use is an effective way. In this study, we discovered that the Src homology region 2 domain-containing phosphatase-1 (SHP-1) agonist SC-43, exhibits potent activity against Gram-positive bacteria, including MRSA. The mode of action studies revealed that SC-43 inhibits the key enzyme coproporphyrin ferrochelatase (CpfC) of the coproporphyrin-dependent (CPD) heme synthesis pathway and interferes with the bacterial porphyrin metabolism. The determination of the structure of CpfC derived from S. aureus (SA CpfC ) in this study allowed us to reveal the inhibitory effect of SC-43 at the molecular level. Animal experiments showed that SC-43 has the potential to become a new anti-MRSA drug. In conclusion, this study discovered a new anti-MRSA activity of a drug currently undergoing clinical trials and simultaneously verified the feasibility of developing new anti-Gram-positive bacteria drugs by inhibiting the CPD pathway.
- Department of Laboratory Medicine, Shenzhen Key Laboratory of Pathogenic Microbiology and Antimicrobial Resistance Surveillance, Shenzhen People's Hospital, (The First Affiliated Hospital, Southern University of Science and Technology; The Second Clinical Medical College, Jinan University), Shenzhen, 518020, China.
Organizational Affiliation:
